医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Chennai Boy Undergoes First of Its Kind Living Donor Liver Transplant in India for Rare Metabolic Disease

2020年09月05日 PM07:24
このエントリーをはてなブックマークに追加


 

CHENNAI, India

A 16 years old boy from Chennai who was suffering from decompensated chronic liver disease due to ‘Cholesteryl ester storage disease’, has undergone successful liver transplant at Gleneagles Global Health City. Across the globe, only 17 such cases have been reported and this is the first such case reported in India. This is one among the rare genetic liver diseases which affects the liver at childhood and further leads to liver failure as the child grows older. It is caused by a mutation in the LIPA gene. As the situation was getting critical, the boy’s mother decided to donate the right lobe of her liver to save her son’s life. The team of 10 experts spearheaded by Dr Joy Varghese, Dr Rajanikanth Patcha, Dr Selvakumar Malleeswaran & Dr Perumal Karnan took 8 hours to perform the complicated surgery amid COVID-19 pandemic and brought the boy back to life.

The boy named Dilli Ganesh was diagnosed with Jaundice at the age of 2. He underwent a detailed evaluation at the Institute of Child Health, Egmore, Chennai. Despite all supportive medications, he suffered from persistent jaundice which progressively increased over time. In the month of July 2020, he was referred to Gleneagles Global Health City in a critical condition. He presented with swollen leg, abdomen distension (swelling of the abdomen) which was a clear sign of Liver cirrhosis. The boy was on his feet from 3rd day post liver transplant and resumed his normal diet from the 5th day onwards. On the 14th day from the date of surgery, the boy was discharged from the hospital.

Dr Joy Varghese, Director -Hepatology & Transplant Hepatology, Gleneagles Global Health City says “When the boy came to our hospital for treatment, he was suffering from distension (swelling) of the abdomen. Before his visit here, he had undergone a procedure to drain the fluid accumulated in the abdomen. Approximately 4.5 liters of fluid were removed from the abdomen and later upon testing of fluid, it was found to be infectious (spontaneous bacterial peritonitis). This condition is extremely critical and the difference between life and death is a matter of short time. Considering the seriousness of this disease our team of expert doctors went on a war footing during the pandemic to save his life”.

“It was the rarest case in India to undergo successful liver transplant for this type of metabolic disorder. Post surgery the boy will be normal like any other child. Mother gave the right lobe of her liver to save her son. stated Dr Rajanikanth Patcha – Head of Liver Transplant Surgery, Gleneagles Global Health City.

“In view of current COVID scenario, a separate team of doctors & nurses worked in dedicated liver transplant OT and ICU to assure patient and donor safety”, added Dr Selvakumar Malleeswaran, Head of Liver ICU – Gleneagles Global Health City.

“Despite his liver-related health issues, the boy emerged successful in his board exams. Having underwent a successful liver transplant, we are sure that the boy will come through with flying colors, breaking the general perception that children who undergo liver transplant may find it difficult to cope with their peers” quoted Dr Perumal Karnan, Head of Department – Paediatrics, Gleneagles Global Health City.

“At GGHC, we always have been a firm proponent of maintaining a high index of suspicion towards less common/rare diseases that may impact the survival and quality of life of our patients. We are cutting edge quaternary healthcare facility where we focus on maintaining and surpassing International standards of care for the best possible outcome for our patients. I congratulate the team of doctors and nurses for giving a lease of life to this exceptionally courageous young man”, said Dr Alok Khullar, CEO – Gleneagles Global Health City, Chennai.

About Gleneagles Global Health City, Chennai

Gleneagles Global Health City, the sprawling 21-acre facility located in Perumbakkam, Chennai, is the largest facility of Gleneagles Global Hospitals India. With a capacity of over 1000 beds and accreditations from leading agencies, the facility is Asia’s most trusted and leading Multi-Organ Transplant Centre. The hospital has undertaken several path-breaking Liver, Neuro, Heart, Lung and Kidney procedures. It is recognized by several national level accrediting agencies. World-class infrastructure, dedicated staff and a commitment for medical excellence are the USPs of this facility. The hospital has several achievements to its credit and continues to work on several pioneering procedures.

Gleneagles Global Hospitals has multi-super speciality hospitals in Bengaluru, Hyderabad, Chennai and Mumbai. The brand is the most preferred hospital group for multi-organ transplants in Asia region. The parent entity of Gleneagles Global Hospitals is IHH Healthcare, a leading premium integrated healthcare provider with a network of 84 hospitals and more than 16,000 licensed beds. It is one of the largest healthcare groups in the world by market capitalisation and is listed in the Main Market of Bursa Malaysia and Main Board of SGX-ST. IHH is a leading player in the home markets of Malaysia, Singapore, Turkey and India, and in their key growth markets of China and Hong Kong.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200905005004/en/

CONTACT

Media Contact: M. Udaya Kumar (Sr Manager), Index PR, udaya.kumar@ketchumsampark.com, +91-9940637802

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease